Frazier Healthcare Partners has once again installed a trio of biotech veterans at the helm and put up cash to get through a vital trial.

SV Health Investors (formerly SV Life Sciences) has closed its sixth fund, hitting its target of $400 million, as the firm itself also registers a numbers…

Frequency Therapeutics has just raised $32 million in a financing round it hopes will help it bring its therapy for noise-induced hearing loss into the clinic.

Axovant Sciences is capitalizing on the attention it has received from welcoming biotech icon David Hung as its new CEO with a $125 million share offering.

Biohaven Pharmaceutical has filed to raise up to $100 million in an IPO for clinical trials of drugs it picked up from AstraZeneca and Bristol-Myers Squibb.

Vifor Pharma has become an independent company following the IPO of its sister unit, Galenica Santé.

BerGenBio has completed its IPO, raising NOK 425 million ($49 million) to invest in a clutch of phase 2 trials of Axl inhibitor BGB324.

Preclinical company Azitra has raised a small bag of cash in its Series A round as it looks to further its work using the skin’s own microbiome for new…

Microbiome biotech Finch Therapeutics has signed a pact with perennial U.S. life sciences dealmaker Takeda to jointly work on FIN-524, a microbial cocktail for…

Venture Capital